Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents

that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1.0 million in the number of shares offered by us would increase (decrease) cash and cash equivalents, additional paid-in capital, total stockholders' (deficit) equity and total capitalization by approximately $             million, assuming an initial public offering price of $            per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. The pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.

        The table above excludes the following shares:

    1,045,834 shares issuable upon the exercise of warrants outstanding as of June 30, 2014, at a weighted-average exercise price of $1.19 per share;
    35,252,515 shares of common stock issuable upon the exercise of options outstanding as of June 30, 2014, with a weighted-average exercise price of $0.19 per share;
    9,000,000 shares of common stock subject to RSUs outstanding as of June 30, 2014;
    1,070,687 shares of common stock reserved for future grants under our 2013 Stock Plan, 2004 Stock Plan and 2001 Stock Plan as of June 30, 2014;
    shares of common stock reserved for future grants under our 2014 Equity Incentive Plan, which became effective in                    2014 (subject to automatic annual adjustment in accordance with the terms of the plan), but with respect to which no awards will be granted prior to the completion of the offering; and
    shares reserved for future issuance under our 2014 Employee Stock Purchase Plan, which became effective in                     2014 but with respect to which no shares will be purchased prior to the effective date of the registration statement of which this prospectus is a part, subject to automatic annual adjustment in accordance with the terms of the plan.

49